INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy in the USA, and the second most lethal form of cancer. 1 While localized disease is readily treatable through surgery and/or radiation, there is no curative intervention for advanced PCa. Advanced PCa typically remains reliant on androgen receptor (AR) signaling throughout disease progression. 2, 3 As a hormone nuclear receptor, AR requires androgen (testosterone or dihydrotestosterone, DHT) binding for activation. Once active, AR binds DNA and initiates transcriptional programs required for proliferation and survival; however, the mechanisms governing these events have remained largely elusive. By contrast, the mechanism by which AR regulates proteases important for prostate function (e.g. prostate-specific antigen (PSA), encoded by KLK3) are well known, and PSA is used clinically to monitor tumor development and progression. 4 Given the exquisite dependence of PCa on AR function, therapy for disseminated disease suppresses AR signaling, achieved by ablation of circulating ligand (androgen deprivation therapy), often used in combination with direct AR antagonists. 2, 5 While initially efficacious, these regimens ultimately fail and castrationresistant prostate cancer develops due to reactivation of the AR signaling axis. 3, 6, 7 At present, there remain no durable means to manage recurrent AR activity and treat castration-resistant prostate cancer; as such developing understanding of AR function and mechanisms to target downstream processes represents a primary focus in the field.
Despite the importance of AR in driving PCa progression, the specific gene networks controlled by AR to induce advanced tumor phenotypes are not well understood. Recent studies revealed a role for AR in regulating PCa cell metabolism particularly as involved in glycolysis and anabolism flux, thereby supporting tumor cell growth. 8, 9 Additionally, AR can indirectly modulate cell cycle progression via mTOR-dependent pathways that lead to Cyclin D1 accumulation, consequent activation of cyclin dependent kinase 4 (CDK4) and phosphorylation/inactivation of the RB tumor suppressor, and subsequent G1-S checkpoint transition. 10 These observations provide clues to the biochemical framework for how AR promotes tumor cell growth, but the molecular basis for AR-dependent phenotypes associated with cell survival, cell migration and metastasis remains largely unsolved. It is notable that genome-wide analyses of AR activity have been performed in cells synchronized in G 0 through steroid deprivation, leaving unresolved the role of AR in mitotically active cells. 9, 11 Studies herein reveal that AR induces differential transcriptional networks in mitotically active cells, unmasking critical new insight into AR function. Molecular dissection demonstrated that networks specific to actively cycling cells can be subdivided into those that are common to all active phases of the cell cycle, versus those that are specifically enriched in distinct cell cycle phases. Networks identified were strongly associated with novel AR cistromes through genome-wide binding analyses, demonstrating the unexpected finding that AR function is significantly expanded in cells committed to the mitotic cell cycle, and that AR function is sensitive to cell cycle position. Functional analyses unveiled novel mechanisms through which AR likely promotes pro-tumorigenic phenotypes, including cell migration and tumor metastases. Of particular significance was the discovery of dihydroceramide desaturase 1 (DEGS1), a desaturase involved primarily in the formation of ceramide, as a key target through which AR promotes pro-metastatic phenotypes. Analyses in human tumor samples further identified DEGS1 as strongly associated with disease progression and poor outcome, outperforming current biomarkers of aggressive disease. Taken together, the studies herein demonstrate that AR signaling is widely expanded in mitotically active cells, and promotes pro-tumorigenic networks underpinning cancer progression.
RESULTS

Androgens induce distinct gene expression programs in cycling cells
Despite the known ability of AR to promote PCa growth and progression, the molecular basis of AR function remains incompletely understood. As the majority of genome-wide analyses have been performed in cells that have exited the cell cycle via steroid deprivation prior to hormone stimulation, it was posited that AR functions supporting lethal tumor phenotypes may be uncovered by assessing AR activity in mitotically active cells. To explore this, human PCa models were utilized to discretely assess cell cycle-dependent effects of androgen and downstream cellular consequences. A baseline for AR activity in resting cells deprived of androgen was established using hormone therapy-sensitive PCa cells synchronized in G 0 through steroid starvation ( Figure 1a ). In parallel, cells cultured in steroid-replete conditions were enriched for distinct phases of cell cycle and subsequently subjected to a 3-h pulse of DHT. Cells were enriched prior to DHT stimulation in early G1 (through use of a CDK4 inhibitor, 87.2% G1-phase), late G1 (via CDK2 suppression, 72.3% G1-phase), in early S (by DNA polymerase inactivation, 42.2% S-phase), in mid-S-phase (through suppression of ribonucleotide reductase, 34.5% S-phase) and G2/M (through release from S-phase into nocodazole, 33.5% G2/M). Robust enrichment in desired phases was validated through flow cytometric analyses ( Figure 1a ). Differentially enriched transcripts were identified through gene expression analyses and compared with unstimulated (G 0 , steroid deprived) cells using a stringent cutoff for both fold change (FC ⩾ 1.5) and false discovery rate (FDR ⩽ 10%). After applying filtering parameters, 1098 transcripts demonstrated differential (positive or negative) cell cycle-regulated expression compared with unstimulated cells in G 0 . To identify androgen-responsive transcriptomes specific to distinct cell cycle phases, genes were clustered using a center-means based approach, considering only expression levels in DHT-stimulated samples. Clustering analysis revealed that maximum upregulation occurred after cell cycle commitment in the early S-phase and beyond, with maximum downregulation observed in the late G1-phase ( Figure 1b ).
Additionally, changes in gene expression were not due to appreciable changes in AR protein levels (Figure 1c , top), or alterations in AR nuclear localization (Figure 1c , bottom). Further, in order to examine whether these expression changes could be mimicked through longer DHT stimulation times, genes altered specifically at 24 h DHT stimulation were examined. 12 Intriguingly, less than 50% of genes changed at 24 h were seen to undergo cell cycle-regulated gene expression in the current study, suggesting that while longer DHT stimulation times may identify a subset of these targets, it is not sufficient to identify a majority of genes differentially regulated by cell cycle phase (Supplementary Figure S1 ). These observations suggest that AR-cell cycle interplay elicits distinct alterations in AR transcriptome in mitotically active cells, dependent on cell cycle phase.
Gene set enrichment analysis identified DHT-responsive gene networks demonstrating cell cycle enrichment specific to actively cycling PCa cells. Briefly, transcripts enriched in individual phases were systematically compared with the remaining data sets, resulting in identification of DHT-responsive gene networks that are upregulated ( Figure 1d , left panel, Supplementary Figure S2 and Supplementary Table 1 ) or downregulated (Figure 1d , right panel, Supplementary Figure S2 and Supplementary Table 1 ) in a phase-restricted manner. As expected, pathways previously identified as androgen regulated (e.g. androgen response and E2F hallmark signatures) [13] [14] [15] were upregulated in the early G1, early S and G2/M phases (Figure 1d , left). Both pathways were subsequently downregulated in the late G1 and late S (Figure 1d , right), suggesting that previously reported androgen-regulated pathways are cell cycle dependent. Additionally, as AR has been recently shown to play an important role in DNA repair, 16, 17 it is notable that hallmark DNA repair and p53-regulated genes were upregulated by DHT exclusively in the S and G2/M phases, suggesting that the capacity of AR to modulate DNA repair is also sensitive to cell cycle position. Finally, pathways exclusively upregulated in the late S-phase include epithelial to mesenchymal transition and inflammatory signaling, pathways known to promote clinical progression in human disease. 18, 19 These observations reveal putative new downstream consequences of AR signaling that provide insight into the means by which this receptor modulates aggressive tumor phenotypes. Mechanistically, these data reveal for the first time that AR signaling elicits distinct transcriptional programs across the cell cycle, and harbors expanded functions in mitotically active cells.
The AR cistrome is expanded in mitotically active cells To discern the molecular basis of the observed expanded gene networks controlled by AR in mitotically active cells, parallel studies were performed to assess the cell cycle-specific AR cistrome. AR-binding sites (ARBSs) were found through chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq), using standard methodology. 20 Statistically significant ARBSs within each phase were identified using MACS peak calling algorithm and a rigorous cutoff (Po 1e − 8 ). As expected, DHT Differentially expressed genes with 10% FDR and min. 1.5 absolute fold change relative to CDT baseline were identified, and hierarchical clustering was performed using replicate means. (c) LNCaP cells were plated in serum-proficient conditions and arrested in the indicated phases and treated with 10 nm DHT for 3 h, followed by immunoblot to assess AR levels (top). Additionally, nuclear fractionation was performed. Briefly, cells were arrested in the phases indicated through drug treatment as previously described, and stimulated with DHT for 3 h. Cells were then harvested, lysed and cell fractionation performed in order to separate nuclear and cytoplasmic fractions. AR protein levels were then assessed within each fraction, with GAPDH serving as a control for the cytoplasmic fraction and Lamin-B as a control for nuclear fraction (bottom). (d) Gene set enrichment analysis analysis using hallmarks of cancer data set. Briefly, enriched gene sets were generated through comparison of the expression data for each individual phase compared with all other phases combined. The top 10 gene sets for each phase (up-and downregulated) are represented (or top sets available in each case). significantly increased AR-binding intensity in all phases when compared with steroid-deprived cells; however, there was noted variance in DHT-induced intensity of AR binding among the cell cycle phases, with G2/M-enriched cells demonstrating the highest intensity, and late G1 and late S exhibiting the weakest intensity (Figure 2a ), perhaps reflective of differential chromatin accessibility in early versus late cell cycle. Using the cis-regulatory element annotation system (CEAS; Figure 2b ), in unstimulated (G 0 ) cells, AR bound intronic (29.2%) and distal intergenic (55.4%) regions, with a small fraction observed in promoter (0-3000 bp from transcriptional start site, 7.2%) and downstream (0-3000 bp from TTS, 6.3%) regions. Comparatively, AR binding in mitotically active cells occurred most frequently (495%) in intronic and distal intergenic regions, indicating a shift in preferential binding regions after DHT treatment and cell cycle activation. Additionally, binding events in early G1, early S and G2/M contained comparable numbers of AR occupied sites (38 620; 41 023; and 40 884, respectively), whereas binding in late G1 and late S was slightly reduced (26 202 and 20 720, respectively; Figure 2c ). These data demonstrate that AR exhibits a differential binding profile among different phases of the cell cycle, consistent with differential DHT-induced gene networks in mitotically active cells.
Further analyses of expanded AR-binding events in mitotically active cells resulted in identification of two major patterns of AR binding, including occupancy at sites that are specific to the mitotic cell cycle but retained in all phases (deemed Cell Cycle Common, or CCC) counterbalanced by occupancy events that are enriched in specific phases of the mitotic cell cycle (Phase-Restricted Binding, or PRB). Comparatively, 28 693 sites were classified as CCC pattern events, and 17 056 meeting the criteria of PRB-binding events (Figures 2c and d ). In the PRB subclass, the early G1, early S and G2/M phases showed similar numbers of phase-restricted binding events, with the late G1-phase exhibiting a marked decrease in AR-binding events, and the late S-phase showing the least evidence of phase-restricted AR occupancy ( Figure 2d ). These collective observations are consistent with the identification of cell cycle-specific AR signaling ( Figure 1 ), and suggest a causative role for AR PRB in the observed phase specific, DHT-dependent transcriptional networks.
The concept that AR performs unique functions in mitotically active cells was further underscored by comparison with previously reported studies of AR cistromes. As shown, ARbinding analyses herein captured the majority of previously reported sites of AR occupancy, wherein cells were arrested in G 0 by steroid deprivation prior to DHT stimulation (Supplementary Figure S3 ). 9, 11 Comparing CCC binding to all post G 0 phases in mitotically active cells illustrated high confidence overlap with binding reported by Massie et al., with over 80% of ARBSs identified in G 0 also exhibiting CCC binding in mitotically active cells. Additionally, 60% of AR occupied sites identified by Wang et al. coincided with CCC binding, with the reduction in overlapped binding likely due to differences in the experimental method (ChIP-Chip performed by Wang et al. vs ChIP-Seq performed in the current study; Figure 3a and Supplementary Figure S3 ). As expected, binding present in G 0 and maintained throughout the cell cycle is exemplified by occupancy at wellcharacterized AR targets such as KLK3 (PSA) and TMPRSS2 (Figure 3b , panel I, and Supplementary Figure S4 ). Notably, a significant fraction of CCC AR occupied sites detected in mitotically active cells is novel. With respect to CCC binding, approximately 70% of the total number of ARBSs was previously unreported (Figure 3a) , illustrated by AR occupancy seen in Figure 3b , panels I and II. Collectively, these findings indicate that AR-binding sites found in G 0 are sustained throughout the mitotic cell cycle, and that AR-binding capacity and function are significantly expanded in mitotically active cells.
While the fraction of novel CCC binding is substantial, assessment of PRB sites reveals further insight into AR function in cycling cells. Over 90% of the PRB events were not identified in the G 0 -enriched data sets ( Figure 3c ), and represent restricted binding events from each cell cycle phase ( Figure 3d ). Collectively, these data indicate that while AR function in G 0 cells is largely preserved in cycling cells, AR function in mitotically active cells is greatly expanded beyond G 0 , eliciting patterns that are unique to the post G 0 cell cycle as well as those that are restricted to specific cell cycle phases. These findings provide the first evidence that AR is differentially programmed in cycling cells, and yield significant new insight into the mechanisms by which AR likely promotes tumor development and progression.
Evidence for differential AR co-factor requirements throughout the cell cycle The observations that androgen induces distinct transcriptional networks in a cell cycle-dependent manner (Figure 1 ), and that AR exhibits an expanded, differential cistrome in mitotically active cells ( Figure 2 ) suggests that cell cycle-specific signaling is directly regulated by AR. To probe the mechanisms and consequence of cell cycle-dependent AR regulation, motif analyses were performed utilizing PRB events. Enriched motifs were divided into three cohorts: constitutively enriched (significantly represented throughout all phases of PRB; Figure 4a ), differentially enriched (enrichment altered throughout two or more PRB phases: Figure 4b ) and phase exclusive enriched (motifs present only in single phase indicated; Figure 4c , Supplementary Figure S5 and Supplementary Table 2 ). Additionally, motifs significantly represented using CCC binding and previously reported (G 0 enriched) data sets were generated for comparison to identify cell cycle-specific alterations. Interestingly, motifs constitutively enriched in all phases of PRB binding were concurrently enriched in CCC and G 0 -enriched data sets (Figure 4a ). This cohort includes FOXA1, which has been well described as an AR pioneer factor, is required for AR activity, and has been shown to contribute to AR reprogramming in tumor transformation ( Figure 4a ). 21, 22 Additionally, the nuclear factor I family member NFIC, which interacts with FOXA1 to regulate AR, was enriched in all data sets evaluated. 23 The AR-binding motif was also enriched within CCC binding, in addition to a number of other previously described AR interactors, including GATA and AP1, consistent with the overlap of CCC motifs and those previously described. 21, 24, 25 Interestingly, the AR-binding motif was enriched in all PRB events except late G1; while lack of enrichment for the AR motif in G1 could be due to the decrease in overall binding in this phase (Figure 4b ), these data suggest potential AR occupancy at non-canonical motifs in late G1. Overall, these data suggest that the requirement for pioneer factor function is retained in all phases of cell cycle, and that AR generally relies on canonical AR-binding motifs across the cell cycle. In contrast, novel motif enrichment was observed in AR events that are phase-restricted. Over 80% of the PRB-enriched motifs (of 25 total) were shown to be novel when compared with those enriched in CCC binding or those identified in previous studies (Figure 4c ), suggesting that PRB-enriched motifs contribute to differential AR function in active cell cycle. This cohort of motifs was enriched for factors with known roles in metastasis and DNA damage, for example, ZEB1 and BRCA1, 26, 27 putting forth the concept that differentially enriched, PRB-specific AR co-factors may not only support cell cycle phase-specific AR function, but likely contribute to AR-induced tumor phenotypes. Taken together, the high degree of motif overlap between previously published binding studies and CCC binding coupled with the lack of overlap when comparing the phase-restricted enriched motifs suggest a likely role for cell cycle-regulated AR co-factors in controlling and facilitating the expanded AR cistrome and regulated gene networks in mitotically active cells.
Expanded AR function in mitotically active cells reveals link to lethal tumor phenotypes
To investigate functional consequence of PRB events, a 'guilty by association' approach was utilized to identify potential targets of phase-restricted AR activity impacted by AR binding. Genes with transcriptional start sites within 30 kb of ARBSs were identified, as depicted in Figure 5a , and subsequently compared with genes identified using published data sets. As expected, genes associated with CCC-binding events overlapped to a high degree with those associated with previous reports (88% of Massie data set validated, 65% of Wang data set validated), replicating the overlap seen using binding alone (Supplementary Figure S6) . Importantly, genes associated with PRB nominated a novel ARregulated gene network, further indicating that the function of AR is expanded in mitotically active cells (Figure 5b) . Genes nominated by proximity to PRB events were then compared with the cohort that exhibited differential DHT-induced gene expression ( Figure 1b) . Strikingly, of the 1098 genes identified as showing phase-specific AR expression, 319 contained PRB in putative regulatory regions (Figure 5c ). To discern the biological impact of PRB-related, androgen-induced transcriptional changes, gene ontology (GO) analyses was performed. Owing to the low number PRB sites in the late G1 and late S phases, ontology analyses were restricted to events in only early G1, early S and G2/M phases. Genes associated with PRB events in early G1 revealed a significant impact on metabolic processes, whereas early S genes unmasked the influence of AR on mitotic progression, including kinetochore assembly, and genes with PRB events in G2/M showed impact on both metabolic processes and cell cycle regulation (Figure 5d ). Combined, these data identify critical new transcriptional networks likely to be controlled by phase-restricted AR binding, exposing a 319 gene set with both phase-restricted binding as well as differential expression. These data suggest for the first time that PRB events are linked to androgen-induced phase-specific transcriptional responses in cycling cells, thus revealing differential AR function throughout the cell cycle.
To explore the biological relevance of the newly identified ARassociated cistrome and transcriptome, the 319 gene set (genes exhibiting both PRB and cell cycle-regulated gene expression) was examined for expression in primary and metastatic PCa in order to identify targets likely to have clinical implications. Genes with altered expression in over 10% of primary disease were removed, so as to isolate those with changes exclusively after metastatic tumor development, nominating 30 prioritized clinically relevant targets (Figure 6a ), of which 19 were upregulated and 11 downregulated. Additionally, a sampling of this subset was validated for PRB using an alternate means of synchronization in order to further assess cell cycle regulation (Figure 6b, top) . Targets were identified that exhibited binding restricted to early G1 (NRDG1, DEGS1 and CENPF), early S (NREP, MKI67 and FOXM1) or G2/M (GRB10, S100A10 and RNF44) and validated by ChIP-qPCR in their respective phases (Figure 6b , middle), thus strengthening these findings. Further, synchronization in an additional hormone therapy-sensitive model system was utilized (VCaP; Supplementary Figure S7 ), and ChIP-qPCR for these sites exhibited PRB in this distinct model system (Figure 6b, bottom) . Functional classification for the prioritized 30 gene set showed association with numerous processes associated with lethal malignancies, including metabolism, cell cycle/proliferation, protein degradation/apoptosis, RNA processing/transcription and metastasis (Figure 6c ). A specific emphasis was placed on metastasis, as AR is known to promote metastatic phenotypes, 28, 29 but the underlying basis for this function is incompletely understood. Within this group, several newly identified genes under likely AR regulation have been previously implicated in at least some aspect of PCa biology. For example, stathmin-1 (STMN1) is associated with epithelial to mesenchymal transition phenotypes, 30 whereas NDRG1 has been suggested to modulate metastatic development, 31 and ARHGAP10 harbors a known role in cellular proliferation. 32 The present study provides an unexpected link of AR to modulation of these factors, strongly suggestive that AR utilizes these pathways to promote clinical tumor progression. Further, semaphorin 4B (SEMA4B), a protein involved in axon extension, was identified in this cohort and has been previously implicated in metastasis of non-small cell lung cancer. 33 Further systematic analysis revealed DEGS1, a desaturase involved in the ceramide synthesis pathway, 34 among the most clinically significant ARregulated genes. As shown, validation via ChIP-qPCR demonstrated phase-restricted AR binding to the DEGS1 regulatory region in early G1 (Figure 7a, top) , with maximum gene expression occurring in the late S-phase (Figure 7a, bottom) . Intriguingly, this phase was where expression of genes involved in epithelial to mesenchymal transition co-occurred, a process also linked to metastasis. Taken together, prioritization of clinical targets with both PRB and differential expression highlighted a 30 gene set over-represented exclusively in metastatic disease, with DEGS1 being prioritized due to its potential in promoting metastasis.
Given the likely impact of DEGS1 on PCa tumor behavior, RNAi silencing was utilized to ablate DEGS1 protein levels (Figure 7b,  top) . Notably, DEGS1 depletion significantly impeded migratory capacity (~50%), suggesting that this newly identified ARregulated target activity promotes pro-metastatic functions (Figure 7b , bottom left, with quantification bottom right). Interestingly, while bioactive lipids ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) have been shown to induce cell proliferation, 35, 36 siDEGS1 had no effect on Brdu incorporation, suggesting that DEGS1 does not alter proliferative potential in this disease type (Supplementary Figure S8) . To further assess the putative role of DEGS1 in PCa progression, a large cohort of patients with localized, high-risk PCa (n = 780) with a median of 11.2 years of clinical follow-up was utilized to determine the clinical relevance of DEGS1. As shown, univariate analyses identified elevated DEGS1 was strongly associated with reduction in freedom from metastasis (Figure 7c , P = 3.4e-15) and rapid biochemical recurrence (Figure 7d , P = 1.9e-06), thus nominating DEGS1 as an AR-regulated predictive marker for metastatic progression. Concordantly, DEGS1 was robustly associated with poor prognosis and reduced survival, both with regard to PCaspecific survival (Figure 7e , P = 7.1e-13) and overall survival (Figure 7f, P = 1.6e-13) . Given the lack of predictive biomarkers to identify aggressive PCa, DEGS1 was further examined through multivariate analyses and elevated DEGS1 levels showed a significant value as an independent predictor of poor outcomes when compared with Gleason score and PSA (Supplementary Figure S9 ). Taken together, these data show for the first time that genes regulated by AR in mitotically active cells are likely drivers of PCa cell progression and metastatic events and unveil DEGS1 as an unexpected AR-regulated gene of clinical relevance (Figure 7g ).
DISCUSSION
Elucidating the mechanisms by which AR induces lethal tumor phenotypes is critical for the development of more effective therapeutic strategies to manage PCa. Herein, new and unexpected functions of AR were unveiled through profiling AR activity in mitotically active cells. Key findings demonstrate that: (i) androgen engages a distinct transcriptional network in post G 0 , mitotically active cells; (ii) the function of AR in actively cycling cells is strikingly expanded during mitotic progression, demonstrating binding events that are specific to mitotically active cells and/or restricted to specific cell cycle phase; (iii) a distinct set of transcription factor motifs are enriched dependent on cell cycle phase; (iv) genes exhibiting dual cell cycle-regulated binding and expression nominate cell cycle-specific targets with relevance in late stage disease; (v) DEGS1 was identified as a cell cycle-specific AR target gene that alters cell migration in PCa; and (vi) DEGS1 independently predicts for metastatic development and poor prognosis. Taken together, these data uncover novel functions for AR in mitotically active cells, allowing the identification of targets with clinical relevance in aggressive disease.
The finding that AR functions differentially in cycling cells when compared with resting cells sheds new light on the function of AR activity in PCa, and is consistent with early studies, suggesting that AR function may be modified by components of the cell cycle machinery. 37 Herein, differential AR activity in the mitotic cell cycle was demonstrated at a genome-wide level, with cell cycle phase altering both AR-chromatin interaction as well as downstream changes corresponding to cell cycle-regulated, DHT-induced transcriptional output. The newly described AR cistromes in mitotically active cells can be divided into binding maintained throughout the cell cycle in cells committed to mitotisis (CCC binding) or binding enriched in a specific cell cycle phase (PRB). The CCC-binding profile notably encompasses the vast majority of previously reported AR-binding sites, largely identified in DHTstimulated cells that were synchronized in G 0 , 9, 11 through additional AR-binding regions were also identified. These binding overlaps include those regulating well-characterized AR target genes (e.g. KLK3 and TMPRS22). Such concordance between previously identified AR cistromes and the CCC-binding profile suggests that AR-binding events in DHT-stimulated G 0 phase cells are largely maintained in actively cycling cells at all phases, and may serve as the 'baseline' of AR function. However, this subset comprised only~30% of the CCC cluster, with nearly 70% of CCCbinding events identifying novel AR functions. An even greater expansion of AR activity was revealed by the PRB subset (~95% novel binding events not previously observed in genome-wide mapping studies enriched in the G 0 phase), further supporting the idea that AR-cell cycle interplay results in novel AR function in cycling cells. PRB-associated genes corresponded to differentially enriched processes, with early G1-phase-restricted binding associated with metabolic processes, early S-phase associated binding with chromosomal organization and G2/M phaserestricted binding associated with mitotic regulation. These . DEGS1 levels were split into low and high expressing tumors, and metastatic events, biochemical recurrence, prostate cancer-specific survival and overall survival reported. (g) Model describing expanded AR functions in mitotically active cells. Binding and gene networks in G0 are held largely consistent throughout cycling cells; however, both AR cistrome associated with phase-restricted binding in addition to gene networks associated with cell cycle-regulated transcriptome encompass expanded AR functions in mitotically active cells. Iterative analyses identified DEGS1 as an AR target with phase-restricted AR binding and cell cycle-regulated gene expression. Finally, DEGS1 was shown to be a robust independent predictor of metastatic development and a predictor of poor prognosis in a large patient cohort.
findings are consistent with previous cellular observations suggesting that AR promotes G1-S transition, 38 and provide some mechanistic basis for this long-appreciated function for AR. In addition to cell cycle-regulated gene networks, new binding and transcriptional targets of AR were identified that assist in defining the mechanism(s) by which AR promotes androgen responsiveness, 13 metabolism, 8, 9 DNA damage 16, 17 and cell cycle transitions. 14, 38 Further, as a subset of prioritized PRB sites were validated in multiple model systems, and using a variety of synchronization methods, the expansion of the AR cistrome in mitotically active cells is a phenomenon likely to be seen across model systems and cell types. The data herein demonstrate that the AR-dependent transcriptional networks governing these cancer-associated activities are regulated as a consequence of cell cycle position, further underscoring the importance of AR-cell cycle interplay in promoting gene expression networks and suggesting implications for tumors with alterations in cell cycle regulatory networks.
The discovery that AR activity is modulated as a function of cell cycle position, and that these functions of AR appear to be critical for AR-mediated tumor progression, leads to provocative hypotheses as to how AR function may be controlled. Data herein demonstrate that AR-binding events in mitotically active cells are enriched for co-occurrence of differential transcription factor motifs ( Figure 4b ), suggesting that AR may depend on differential cooperating factors to elicit cell cycle-specific transcriptional signaling. Known motifs of co-factors thought to be requisite for AR activity (e.g. 'pioneer factors', such as FOX and GATA) 21, 39, 40 associated with AR binding irrespective of cell cycle position, consistent with the importance of these factors for AR activity. However, selective enrichment of putative transcriptional cooperating factors were observed that have been previously linked to malignant phenotypes. Exemplifying this cohort in the G1-phase are ZEB1, recently shown to be strongly associated with PCa migration and invasion, 26, 41 and BRCA1, which has a welldescribed role in DNA repair and transcriptional regulation. 42, 43 Ongoing studies are directed at interrogating the molecular impact of each motif enrichment and putative cooperating cofactor activity on AR function, both with regard to CCC and PRB events. Such regulation is likely to be complex, as 25 motifs in total were exclusively associated with PRB binding in a single phase of cell cycle. Strikingly, PRB-enriched motifs showed little overlap with CCC-associated motifs, congruent with the expanded cistrome seen in mitotically active cells. Notable within this subset is enrichment of CTCF in the early G1-phase, as CTCF is involved in nucleosome positioning and chromosome remodeling. 44 CTCF was previously shown to be associated with AR binding, 45 but this interaction was contingent upon loss of FOXA1 and subsequent expansion of AR cistrome; thus, the present data bring forth new understanding of CTCF-AR interplay. Additionally, the c-myc motif was exclusively enriched in early G1; this motif was shown to be enriched in AR binding in clinical castration-resistant prostate cancer samples 46 and is known to be important for PCa survival, upregulated in PCa, and associated with aggressive disease. [47] [48] [49] [50] As AR and c-myc are also known to regulate similar metabolic pathways, 51 and have been seen to co-regulate target genes, 52 the phase-specific enrichment provides the context to determine how these two major transcriptional effectors of cancer progression act in concert to promote disease progression. Overall, these analyses implicate cell cycle-specific transcriptional regulators as cooperating with AR to promote disease progression, and provide the molecular basis for further delineation of cell cycle-specific AR function.
Complementing these findings, multiple components of the cell cycle machinery have been shown to directly interact with and influence AR activity, and may also contribute to cell cycle-specific AR function. The early G1 kinase CDK6 enhances AR activity in reporter assays, 53 and the CDK4/6 catalytic subunit Cyclin D1 binds and modulates AR activity in a target-selective manner. [54] [55] [56] Notably, a highly oncogenic variant of Cyclin D1 associated with advanced disease induces mis-regulation of AR and directs expression of gene networks promoting metastatic phenotypes. 57 In late G1, Cyclin E can enhance AR transcriptional activity through direct interaction, suggesting an intricate balance between these factors may play a role in the cell cycle-regulated activity seen in the G1-phase. 58 Additionally, the RB/E2F1 axis, which controls G1-S transition, has been shown to regulate AR activity. AR expression is directly regulated by E2F1, and RB loss therefore results in enhanced AR expression and output. 14 Finally, AR activity in G2/M is intricately modulated, as CDK1 can inhibit AR activity through phosphorylation on serine 308, and the phosphatase Cdc25b enhances AR activity. 59, 60 Determining the contribution of these factors in controlling cell cycle-specific AR activity will be of high priority, given the advent of preclinical findings assessing CDKtargeting therapeutics in PCa and trials for clinical assessment for CDK4/6 inhibitors. For example, the CDK4/6 inhibitor palbociclib was shown to suppress PCa growth in model systems and to selectively cooperate with AR-directed therapies, 61 and clinical evaluation is currently in progress (http://clinicaltrials.gov, NCT02059213). The present study has defined AR activity in response to palbociclib, both with regard to AR binding and downstream transcriptional regulation, and will allow for future studies directed at maximizing AR suppression in the presence of palbociclib.
The discovery of previously unrecognized AR transcriptional targets that promote tumor progression represents a major advance in our understanding of PCa progression. The newly identified AR-regulated genes are linked to diverse processes relevant to cancer progression, including metastasis, RNA processing/transcription, cell cycle/proliferation, metabolism and protein degradation/apoptosis. While each represents a significant advance in understating of AR function, the link to metastasis was particularly striking. Several newly identified AR-regulated genes in this class (STMN1, NDRG1 and ARHGAP10/ARHGAP21) have been tentatively linked to metastatic progression, but the mechanisms governing expression were unknown. 30, 31 The Rho/ Rac signaling pathway was recently identified as a driver in promotion of metastatic phenotypes in PCa, as part of cooperation between AR and DNA-repair factors. 29 Here, the Rho GTPaseactivating protein ARHGAP10 was found to undergo cell cyclespecific regulation and as such will be of further interest to elucidate the extent of the interplay between AR, cell cycle components and DNA damage factors in controlling metastasis. SEMA4B, a protein involved in inhibition of axonal extension, was also upregulated in metastatic disease. While a role for SEMA4B in PCa has not yet been described, in models of non-small-cell lung cancer it was shown to inhibit proliferation and cell metastasis. 33 Finally, findings herein identified DEGS1 as a novel, robust predictor of metastatic disease and poor outcome in PCa that is regulated by AR. DEGS1 is poorly understood at the molecular level, but is known to be involved in ceramide synthesis, and as shown here, promotes cell migratory phenotypes in PCa. These findings strengthen and complement preliminary preclinical observations in esophageal carcinoma linking DEGS1 to cell migration. 34 Analyses herein of human tissues demonstrated that DEGS1 upregulation is tightly linked with a decrease in freedom from biochemical recurrence, freedom from metastasis and overall survival, underlying importance as an AR-induced effector of lethal disease phenotypes. Strikingly, DEGS1 independently predicted for aggressive disease, on par with currently utilized standards (PSA and Gleason score). As Gleason score is currently the strongest currently utilized predictor of poor outcome, added biomarkers with the ability to predict for disease progression such as DEGS1 are critical. Translational potential is also noted, as a recent study examining the use of a sphingosine kinase inhibitor ABC294640 in PCa was seen to additionally inhibit DEGS activity, suggesting that drugs specifically targeting DEGS1 may be of therapeutic import. 62 Taken together, molecular assessment of AR activity not only reveals differential function across the cell cycle and illuminates new understanding of the mechanisms by which AR promotes disease progression, but underscores the importance of discerning cancer-promoting transcription factor function in mitotically active cells. The present findings yield critical new insight into AR function and nominate downstream effectors of AR activity as potentially impactful therapeutic targets and biomarkers of lethal disease phenotypes.
EXPERIMENTAL PROCEDURES Cell cycle arrest
Cells were plated in hormone-replete media 24 h prior to treatment. Cells were treated 24 h prior to harvest with (final concentration): 0.5 μM PD-0332991 (early G1-phase enrichment), 5 μg/ml roscovitine (late G1phase enrichment), 2 μg/ml aphidicolin (early S enrichment), 1 mM hydroxyurea (late S enrichment), 2 μg/ml aphidicolin for 15 h, followed by washout and treatment with 50 ng/ml nocodozole for 9 h (G2/M phase enrichment).
Gene expression analysis
Cells were arrested as described above and stimulated with 10 nM DHT for 3 h prior to harvest. mRNA was processed and transcriptional analyses performed. Details for full gene expression analyses are available in Supplementary Materials and Methods.
ChIP-Seq. Cells were arrested as described above, with biological triplicate for each condition, and ChIP-Seq performed as previously described. 20 Extended details for ChIP-Seq data analyses are available in the Supplementary Methods.
RNA interference. Cells were seeded at equal density in hormone-replete conditions. Cells were then transfected for 6-8 h in serum-free conditions with either control or siDEGS1 according to the manufacturer's specifications. Cells were maintained for an additional 72 h in serum-replete media, treated as specified and harvested at indicated time point. Immunoblot analysis was conducted to confirm knockdown at 72 h post transfection.
Clinical analyses. Microarray data on radical prostatectomy samples were obtained from the Mayo Clinic and profiled using the Affymetrix Human Exon 1.0 ST array as described previously. 63, 64 Two independent cohorts of patients: Mayo Clinic I (MCI, n = 545) 63 and Mayo Clinic II (MCII, n = 235), 64 were pooled into the MC cohort (N = 780) and evaluated. Microarray data were downloaded from the NCBI Gene Expression Omnibus (GSE46691, GSE62116) DEGS1 expression was split into high versus low by comparing the top one-third of DEGS1 expression versus the bottom two-third in each cohort. Kaplan Meier curves for freedom from biochemical recurrence, freedom from metastasis, prostate cancer-specific survival and overall survival, and P-values were generated using the log-rank test. Cox regression was used for both univariate and multivariate analyses. In the multivariate analysis: age was treated as a continuous variable; PSA was grouped into low (o10), intermediate (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and high (420); surgical margin status, seminal vesicle invasion, extracapsular extension and lymph node invasion were treated as binary variables; and Gleason score was grouped into low (o7), intermediate 7 or high (8) (9) (10) . Stratification by cohort was used when performing pooled analysis to account for baseline differences between cohorts. 65 
